Amadori albumin in type 1 diabetic patients - Correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries

被引:128
作者
Schalkwijk, CG
Ligtvoet, N
Twaalfhoven, H
Jager, A
Blaauwgeers, HGT
Schlingemann, RO
Tarnow, L
Parving, HH
Stehouwer, CDA
van Hinsbergh, VWM
机构
[1] Vrije Univ Amsterdam, Acad Hosp, Dept Clin Chem, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Acad Hosp, Dept Internal Med, NL-1007 MB Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Inst Cardiovasc Res, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam, Inst Extramural Med, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands
[6] TNO, Gaubius Inst, PG, Leiden, Netherlands
[7] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
关键词
D O I
10.2337/diabetes.48.12.2446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonenzymatic glycation is increased in diabetes. Most studies so far have focused on the role of advanced glycation end products (AGEs) in vascular complications, whereas the role of early glycation Amadori-modified proteins, which is the predominant form of glycated proteins, has not been systemically investigated in humans. Fire developed an antiserum against glycated human serum albumin (HSA) and used this to study the role of early glycation products in vascular complications in type 1 diabetic patients. Amadori albumin mas determined to be the recognition epitope of the antiserum. The antibody recognized a specific glucose adduct and a conformational component specific for human albumin in Amadori albumin, with no recognition of AGEs. Plasma Amadori albumin levels mere significantly higher in type 1 diabetic patients (n = 55) than in healthy control subjects (n = 60) (39.2 +/- 9.9 vs. 20.9 +/- 4.0 U/ml, P < 0.0005). Amadori albumin correlated with levels of plasma markers of endothelial function von Willebrand factor (r = 0.29, P < 0.05) and vascular cell adhesion molecule-1 (r = 0.41, P < 0.005), but not soluble E-selectin. in addition, Amadori albumin immunoreactivity was detected in the capillaries of retinas of diabetic patients. Plasma levels of Amadori albumin mere determined in a second group of type 1 diabetic patients with long-standing diabetes with (n = 199) or without (n = 192) diabetic nephropathy. Patients with nephropathy had higher Amadori albumin levels than did those without it (50.9 +/- 9.5 vs. 45.1 +/- 6.3 U/ml, P < 0.0005). Age-, sex-, and diabetes duration-adjusted analyses showed that nephropathy was significantly associated with Amadori albumin with an odds ratio (OR [95% CI]) of 1.11 [1.08-1.15] per U/ml increase. After additional adjustment for levels of creatinine, glycated hemoglobin, cholesterol, triglycerides, blood pressure, preexistent retinopathy, and cardiovascular disease, Amadori albumin continued to be significantly associated with nephropathy (OR 1.06 [1.01-1.11]) per U/ml increase. Our results are consistent with a proposed pathophysiological role of Amadori albumin in microvascular complications of type 1 diabetic patients.
引用
收藏
页码:2446 / 2453
页数:8
相关论文
共 38 条
[1]   Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells [J].
Amore, A ;
Cirina, P ;
Mitola, S ;
Peruzzi, L ;
Gianoglio, B ;
Rabbone, I ;
Sacchetti, C ;
Cerutti, F ;
Grillo, C ;
Coppo, R .
KIDNEY INTERNATIONAL, 1997, 51 (01) :27-35
[2]  
ARMBRUSTER DA, 1987, CLIN CHEM, V33, P2153
[3]   FORMATION OF IMMUNOCHEMICAL ADVANCED GLYCOSYLATION END-PRODUCTS PRECEDES AND CORRELATES WITH EARLY MANIFESTATIONS OF RENAL AND RETINAL DISEASE IN DIABETES [J].
BEISSWENGER, PJ ;
MAKITA, Z ;
CURPHEY, TJ ;
MOORE, LL ;
JEAN, S ;
BRINCKJOHNSEN, T ;
BUCALA, R ;
VLASSARA, H .
DIABETES, 1995, 44 (07) :824-829
[4]   Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus [J].
Berg, TJ ;
Bangstad, HJ ;
Torjesen, PA ;
Osterby, R ;
Bucala, R ;
Hanssen, KF .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (06) :661-665
[5]   AMINOGUANIDINE PREVENTS DIABETES-INDUCED ARTERIAL-WALL PROTEIN CROSS-LINKING [J].
BROWNLEE, M ;
VLASSARA, H ;
KOONEY, A ;
ULRICH, P ;
CERAMI, A .
SCIENCE, 1986, 232 (4758) :1629-1632
[6]   ADVANCED GLYCOSYLATION PRODUCTS QUENCH NITRIC-OXIDE AND MEDIATE DEFECTIVE ENDOTHELIUM-DEPENDENT VASODILATATION IN EXPERIMENTAL DIABETES [J].
BUCALA, R ;
TRACEY, KJ ;
CERAMI, A .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (02) :432-438
[7]   EFFECTS OF AMINOGUANIDINE ON PERIPHERAL-NERVE FUNCTION AND POLYOL PATHWAY METABOLITES IN STREPTOZOTOCIN-DIABETIC RATS [J].
CAMERON, NE ;
COTTER, MA ;
DINES, K ;
LOVE, A .
DIABETOLOGIA, 1992, 35 (10) :946-950
[8]   Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice [J].
Clements, RS ;
Robison, WG ;
Cohen, MP .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1998, 12 (01) :28-33
[9]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[10]  
Cohen MP, 1996, J AM SOC NEPHROL, V7, P183